Janus Henderson Group PLC raised its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 21.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,081,099 shares of the company’s stock after purchasing an additional 722,226 shares during the period. Janus Henderson Group PLC owned approximately 9.46% of Soleno Therapeutics worth $206,016,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. HighVista Strategies LLC bought a new stake in shares of Soleno Therapeutics in the third quarter valued at approximately $560,000. Holocene Advisors LP raised its holdings in Soleno Therapeutics by 10.8% in the 3rd quarter. Holocene Advisors LP now owns 594,364 shares of the company’s stock valued at $30,009,000 after acquiring an additional 57,913 shares in the last quarter. Checkpoint Capital L.P. raised its holdings in Soleno Therapeutics by 194.4% in the 3rd quarter. Checkpoint Capital L.P. now owns 57,983 shares of the company’s stock valued at $2,928,000 after acquiring an additional 38,288 shares in the last quarter. Fred Alger Management LLC bought a new stake in shares of Soleno Therapeutics during the 3rd quarter valued at $310,000. Finally, Martingale Asset Management L P acquired a new stake in shares of Soleno Therapeutics during the 3rd quarter worth $1,110,000. Institutional investors and hedge funds own 97.42% of the company’s stock.
Analyst Upgrades and Downgrades
SLNO has been the subject of several recent analyst reports. Oppenheimer upped their price objective on shares of Soleno Therapeutics from $65.00 to $73.00 and gave the stock an “outperform” rating in a research report on Monday, October 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Soleno Therapeutics in a report on Friday, September 20th. Robert W. Baird reiterated an “outperform” rating and set a $72.00 price target on shares of Soleno Therapeutics in a research report on Monday. Stifel Nicolaus restated a “buy” rating and set a $74.00 price objective on shares of Soleno Therapeutics in a research report on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Soleno Therapeutics in a report on Monday. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $74.83.
Soleno Therapeutics Price Performance
SLNO stock opened at $51.16 on Wednesday. Soleno Therapeutics, Inc. has a 1 year low of $27.27 and a 1 year high of $60.92. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -15.41 and a beta of -1.47. The company has a 50 day simple moving average of $53.63 and a 200 day simple moving average of $48.73.
Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($1.22). On average, equities research analysts anticipate that Soleno Therapeutics, Inc. will post -3.76 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, CEO Bhatnagar Anish sold 21,633 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $49.43, for a total value of $1,069,319.19. Following the sale, the chief executive officer now owns 719,553 shares of the company’s stock, valued at $35,567,504.79. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO James H. Mackaness sold 8,077 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $49.43, for a total value of $399,246.11. Following the transaction, the chief financial officer now directly owns 119,172 shares of the company’s stock, valued at approximately $5,890,671.96. This represents a 6.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,818 shares of company stock valued at $1,622,194 in the last 90 days. Corporate insiders own 12.30% of the company’s stock.
Soleno Therapeutics Profile
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Featured Stories
- Five stocks we like better than Soleno Therapeutics
- Investing In Preferred Stock vs. Common Stock
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Netflix Is On Track To Hit $1,000 By Christmas
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Want to see what other hedge funds are holding SLNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report).
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.